Genzyme (GENZ) Presents Preliminary Phase 2 Results of Clolar(R)
More News related to GENZ
- Trading Outlook for MannKind Corp. Issued by InvestorSoup.com
- Trading Outlook for Metabasis Therapeutics Issued by StockPreacher.com
- Trading Outlook for Incyte Corp. Issued by StockPreacher.com
- Trading Outlook for Elan Corp. Plc. Issued by InvestorSoup.com
- PTC Therapeutics Initiates Phase 2 Clinical Trial of ataluren (PTC124(R)) in Patients with Hemophilia
More News related to Corporate News
- LDK Solar (LDK) Announces Civil Order to Freeze Any Payments to Guarantee Banks From Q-Cell Payments
- Kinross Gold (KGC) Receives Authorization to Re-Commence Exploration on Project in Ecuador
- Sanofi-aventis (SNY) and Regeneron Pharmaceuticals (REGN) to Expand Global Collaboration
- Stryker (SYK) Announces Two Acquisitions
- Adobe (ADBE) Cutting 680 Full-Time Jobs to Align Costs with '10 Operating Plan
Today at ASCO, Genzyme Corp. (Nasdaq: GENZ) reported preliminary data from a fully-enrolled pivotal, phase 2 study examining the safety and effectiveness of Clolar(R) as a single agent in previously untreated, older adult patients with acute myelogenous leukemia who are unlikely to benefit from conventional "7+3" anthracycline plus cytarabine-based induction chemotherapy.
Results from the CLASSIC-II clinical trial show that patients with unfavorable prognostic factors who received single agent clofarabine exhibited a 45% overall remission rate based on investigator assessment, with manageable treatment-related side effects. Importantly, the 30 day all-cause mortality, one of the secondary endpoints in this study, was only 9.6%, which compares favorably to existing treatment options.
Genzyme Corporation operates as a biotechnology company worldwide.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
